. Author manuscript; available in PMC: 2013 Jul 15.

Published in final edited form as: Lab Invest. 2011 Feb 14;91(4):598–608. doi: 10.1038/labinvest.2010.205

Table 1.

Increased numbers of CD4⁺CD25⁺ regulatory T cells and CD11b⁺Gr-1⁺ cells in the spleens of the tumor-bearing mice

Cell number ( × 10⁶)	Normal mice	Tumor-bearing mice (Control group)	Tumor-bearing mice (Sorafenib group)
CD4	32.8±4.3	32.3±7.4	36.8±6.2
CD8	20.9±2.8	23.7±5.4	21.8±3.7
CD4⁺CD25⁺	3.6±0.5^a	5.3±1.2	2.8±0.5^a
CD11b⁺Gr-1⁺	7.2±0.9^a	19.2±4.4	5.6±0.9^a

Spleens from normal or tumor-bearing mice treated with or without Sorafenib were prepared into single cell suspension. After red cell lysing and wash, cells were suspended, counted, and stained with antibodies for CD3, CD4, CD8, CD25, CD11b and Gr-1, then analyzed by flow cytometry. The absolute numbers of cells were caculated based on the total number of splenocytes and percentages of CD4⁺, CD8⁺, CD4⁺CD25⁺ and CD11b⁺Gr-1₊ cells in spleens. Values represent mean ± SD from 4 mice per group from one of two independent similar experiments.

vs control group P value <0.05.